The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment. GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.

Start Date01 Jan 2022

Sponsor / Collaborator

Shanghai Huashan Hospital

EUCTR2019-004458-27-DK

/ TerminatedPhase 4IIT

Optimizing the fertility potential of bilateral cryptorchidism by treatment with adjuvant kryptocur.

Start Date23 Sep 2020

Sponsor / Collaborator

Rigshospitalet

NCT04037254

/ Active, not recruitingPhase 1/2IIT

Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)

This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding niraparib to the usual care may lower the chance of prostate cancer growing or returning.

Start Date08 Oct 2019

Sponsor / Collaborator

NRG Oncology

[+1]

100 Clinical Results associated with Gonadorelin Hydrochloride

100 Translational Medicine associated with Gonadorelin Hydrochloride

100 Patents (Medical) associated with Gonadorelin Hydrochloride

239

Literatures (Medical) associated with Gonadorelin Hydrochloride

01 Apr 2026·THERIOGENOLOGY

Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols

Article

Author: Carvalho, Laís Reis ; Fernandes do Vale, Leonardo Silva ; de Souza, José Camisão ; Vicente, Matheus Pedroso ; de Sousa Sales, José Nélio ; Lemos, Lucas Araujo ; Souza Simões, Luiz Manoel

The objective was to evaluate the fertility of Bos indicus cows submitted to an ovulation synchronization protocol without estrogen (E2). In experiment 1, injectable P4 (P4i) was administered 10 days (D-10) before the TAI protocol. On D0, cows received one intravaginal P4 device and estradiol benzoate (EB; Control) or buserelin acetate (GnRH/EC and 2GnRH). On D8, devices were removed, and all cows received eCG and PGF2α. Additionally, cows received estradiol cypionate (EC) on D8 (Control and GnRH/EC) or buserelin acetate on D10 (2GnRH). In Experiment 2, cows in the Control group underwent a protocol similar to Experiment 1. Cows in the GnRH/EC, 2GnRH/48h, and 2GnRH/54h groups were pre-synchronized with an intravaginal P4 device (D-7) and received gonadorelin and an intravaginal P4 device on D0. P4 devices were removed on D8, and all cows received eCG and PGF2α. Furthermore, the GnRH/EC group received EC, and cows in the 2GnRH/48h and 2GnRH/54h groups were administered GnRH 48 h (h) after removal of the P4 device. TAI was performed 48 (2GnRH/48h) or 54h (2GnRH/54h) after removal of the P4 device. In all experiments, the follicular diameter on D8 was greater in cows that received GnRH on D0 (P ≤ 0.01) as well as a greater ovulation rate on D0 (P ≤ 0.01). Furthermore, estrus expression was greater in cows receiving EC (P = 0.001; Exp. 2). P/AI was greater in the Control group (P = 0.001; Exp. 2). In conclusion, removal of estradiol in ovulation synchronization protocols resulted in lower fertility relative to E2-based controls.

01 Apr 2026·THERIOGENOLOGY

Stress-related cortisol and progesterone concentrations influence the success of ovulation induction in estrous cats

Article

Author: Ozturk, Tunahan ; Ayalp-Erkan, Aslihan ; Ozturk, Buse ; Cetinkaya, Yusuf Bilal ; Guner, Baris

Queens are induced ovulators, and ovulatory success varies with hormonal status and stress. This study aimed to investigate the stress and hormone related factors influencing ovulatory success in 78 queens induced to ovulate by vaginal stimulation (VS), GnRH (50 μg gonadorelin), and human chorionic gonadotropin (hCG, 250 IU) in domestic cats. Before ovulation induction, stress scores, serum anti-Müllerian hormone (AMH) concentrations, age, body weight, and estrus day were recorded. Serum luteinizing hormone (LH), cortisol, and progesterone were determined to characterize hourly from 0 to 4 h post-induction, and estradiol and progesterone were measured once daily for six days. Ovulation was histologically confirmed and progesterone concentrations were ≥1 ng/mL were classified as ovulated. The proportion of ovulated queens differed (p < 0.05) among treatments (VS; 46.2 %, GnRH; 73.1 %, hCG; 100 %). There was a positive correlation between the stress score and both serum cortisol and progesterone concentrations. A significant difference in LH concentrations was observed between ovulated and non-ovulated queens (p < 0.05). Ovulatory response in VS and GnRH groups of queens was influenced by several physiological factors, with individuals at more advanced estrus days and those exhibiting greater estradiol and lower AMH concentrations associated with a greater likelihood of ovulation (p < 0.05), whereas increasing stress score, advancing age, elevated cortisol and progesterone concentrations were associated with reduced ovulation rates (p < 0.05). Additionally, a marked post-induction increase in estradiol concentrations in hCG-treated queens (p < 0.05). Overall, ovulatory success in queens was influenced by induction method, estrus stage, stres, estradiol and AMH concentrations. Stress-associated adrenal activation may impair LH dynamics and reduce the likelihood of ovulation, whereas hCG maintained consistent efficacy even under heightened stress conditions.

01 Feb 2026·JOURNAL OF DAIRY SCIENCE

Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows

Article

Author: Melo, D B ; Marques, T C ; Wiltbank, M C ; Salman, S ; Silvestre, F ; Lima, F S ; Wallace, R ; Coelho, W M ; Silva, M C G M ; Pẽna, G ; Bruno, R G S ; Cleale, R M ; Short, T H ; Monteiro, P J L ; Martinez, R

The objective of this study was to evaluate the effect of administering 200 µg versus 100 µg of GnRH as gonadorelin hydrochloride (Factrel; Zoetis, Parsippany, NJ) at the first GnRH injection (G1) of the breeding Ovsynch in a Double-Ovsynch (DO) protocol on pregnancy per artificial insemination (P/AI) at first service in lactating dairy cows. The study was conducted across 4 commercial dairies located in California (n = 2) and Wisconsin (n = 2). We also assessed the effect of GnRH dose on ovulatory response and LH release. Each week, cows were blocked in a 2 × 2 factorial design by parity (primiparous or multiparous) and GnRH dose (100 µg or 200 µg) within each herd. The primary outcome was P/AI following estrus synchronization and timed AI. Cows were excluded if they were inseminated outside the synchronization window, culled before pregnancy diagnosis, or missed scheduled GnRH or PGF_2α treatments. Dinoprost tromethamine (12.5 mg/mL; Lutalyse HighCon, Zoetis) served as the PGF_2α source. A total of 6,621 cows met the inclusion criteria (2,525 primiparous; 4,096 multiparous). Of these, 3,310 received 100 µg GnRH (2 mL), and 3,311 received 200 µg GnRH (4 mL). A subset of 505 cows from herd A underwent transrectal ultrasonography to assess ovulatory response at G1 and 7 d later (first PGF2α of DO), with concurrent serum progesterone (P4) sampling. An additional subset of 18 cows had blood samples collected at 0 (pretreatment) and at 30, 60, 90, 120, 150, 180, 210, 240, 300, and 360 min post-treatment to measure LH concentrations. The final statistical model for P/AI included fixed effects of treatment, parity, and their interaction, with random effects of herd, service sire, herd-by-treatment-by-parity, and month fresh nested within herd-by-parity. Treatment and parity significantly affected P/AI, although their interaction was not significant. Least squares means for P/AI were higher with 200 µg than 100 µg GnRH (51.8% vs. 48.6%). When stratified, the effect in primiparous cows was minimal (52.8% vs. 51.8%), but substantial in multiparous cows (50.7% vs. 45.4%). Cows treated with 200 µg GnRH had a greater ovulatory response than those receiving 100 µg (83.0% vs. 70.8%). Parity also influenced ovulation, though no treatment-by-parity interaction was observed. When P4 was categorized (Low <3.0 ng/mL, High ≥3.0 ng/mL), a 3-way interaction emerged: in primiparous cows with Low-P4, ovulation was greater with 200 µg; in multiparous cows with High-P4, ovulation was greater with 200 µg. No treatment effect was observed on P4 concentrations 7 d post-treatment. Cows receiving 200 µg GnRH had higher peak LH and area under the curve than those receiving 100 µg, though peak timing did not differ. In summary, increasing the GnRH dose to 200 µg at G1 of the breeding Ovsynch in a DO program improved LH release, ovulatory response, and first-service P/AI, with the greatest benefit in multiparous cows.

News (Medical) associated with Gonadorelin Hydrochloride

23 Apr 2025

·www.prnewswire.com

ProRx Pharma Continues to Expand Preventative Health Portfolio with Six New Products

Expanded Product Line Targets Growing Demand for Proactive Wellness Solutions in Clinics, Med Spas, 503A Pharmacies, and Telehealth Practices Across the United States WEST PALM BEACH, Fla. and EXTON, Pa., April 23, 2025 /PRNewswire/ -- ProRx Pharma, the leading health and wellness 503B outsourcing facility, today announced the addition of six new injectable products designed to support the rising demand for preventive care: Gonadorelin, Liraglutide, Vitamin D3, and Phenylephrine HCl as well as two Tri-Mix injection options. These high-quality standalone injectables are now available for bulk shipping to licensed medical facilities in 26 states and for direct-to-consumer shipping nationwide through ProRx's growing network of 503A pharmacies, clinics, med spas and telehealth providers. "Patients are taking charge of their health like never before," said Kurt Lunkwitz, chief operating officer at ProRx. "Physicians are following suit, integrating wellness therapies into their practices to meet the demand for more proactive, functional care. This trend is only going to continue. The continued expansion of our health and wellness line is a direct response—and a step toward making preventative health more accessible and streamlined." What's New: The Products Each of the six new offerings comes with its own National Drug Code (NDC) number and an extended Beyond Use Date (BUD), providing both flexibility and longer shelf life for providers: Gonadorelin ( 1 mg/mL, 6 mg / 6 mL vial ) A gonadotropin-releasing hormone agonist which is used in fertility medicine and to treat amenorrhea and hypogonadism. Gonadorelin may promote testosterone production; may support fertility, libido, and hormonal balance. Liraglutide ( 0.75 mg, 1 mg, 2 mg, 3 mg [custom dosing] ) A powerful GLP-1 receptor agonist for weight and blood-sugar management. Liraglutide may aid in weight loss, appetite suppression, and blood-sugar control. Vitamin D3 ( 50,000 IU/mL, 5 mL vial ) A high-dose solution for those with critically low vitamin D levels. Vitamin D3 may support immune function, bone health, mood, and Vitamin D repletion. Tri-Mix #1 ( 30 mg / 1 mg / 10 mcg/mL, 5 mL vial ) The first of two strength offerings for erectile dysfunction (ED) therapy. Tri Mix #1 may improve erectile response through smooth muscle relaxation and blood flow. Tri-Mix #2 ( 30 mg / 2 mg / 20 mcg/mL, 5 mL vial ) A stronger ED therapy offering. Tri-Mix #2, may provide more ED support for patients needing increased vasodilation. Phenylephrine HCl ( 0.1% 2 mL vial) A critical safety solution for patients using Tri-Mix therapies. Phenylephrine HCl may reverse prolonged erection or priapism due to ED therapy. The introduction of these six new products comes on the heels of ProRx announcing its first four preventative-care offerings the first week of April: Sermorelin, NAD+, Glutathione and MIC/B6/B12. Exclusive Launch at A4M Conference ProRx is showcasing its full line of preventative-care products at the A4M 33rd Annual Spring Conference taking place April 24-26 in West Palm Beach, Florida. At Booth 527, attendees will get an exclusive first look at all 10 products in the new product line and be able to speak with ProRx's experts about the company's compliance and quality-assurance programs. About ProRx Pharma ProRx Pharma is an FDA-registered cGMP facility focused on providing essential compounded medications to meet the need for medications on the FDA drug shortage and bulks list with an emphasis on preventative health. The company produces products and formulations for medical institutions, physician offices, and 503A pharmacies, with a specialization in producing high-quality products to ensure patients have access to the medications they need during critical shortages. For more information, visit SOURCE ProRx Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

09 Feb 2021

·www.biospace.com

Antev Appoints Amit Kohli as Chief Executive Officer

LONDON, UK / ACCESSWIRE / February 9, 2021 / Antev Ltd ("Antev" or "the Company"), a late clinical-stage drug development company advancing the drug teverelix to treat prostate cancer and related indications, today announces the appointment of Amit Kohli as Chief Executive Officer ("CEO"). Mr Kohli will be responsible for leading Antev's corporate strategy and operational and clinical development and will oversee the Company's advance along the clinical pathway towards commercialisation for its lead indication, teverelix, a novel gonadotrophin releasing hormone ("GnRH") antagonist for the treatment of hormone sensitive advanced prostate cancer. With over 25 years of senior executive and leadership roles across both public and private companies operating within the healthcare sector, Mr Kohli has strong cross functional experience that straddles clinical drug development, regulatory affairs, manufacturing, sales, marketing and finance. "Amit comes to us from multiple senior executive positions in the life science industries. With his breadth of experience spanning key facets of our industry and at an exciting and important stage in Antev's development, we are delighted to welcome him and very much look to benefitting substantially from his commercial vision and clinical development background", said Oliver Bates, Co-Founder and Non-Exec Chairman of Antev Limited. "I am delighted to join Antev at a key stage in the company's development," commented Mr Kohli. "Teverelix, a novel GnRH Antagonist, offers a potential life-saving treatment for hormone sensitive advanced prostate cancer patients. I am very excited by the Phase 2 clinical advance of teverelix , validating its well differentiated pro will give Urologists and Uro-Oncologists an option to administer a longer acting, efficacious treatment, which has a milder side-effect profile, driving higher compliance. Furthermore, FDA/EMA guidelines allow a quick and cost-effective pathway towards regulatory approval with a single arm pivotal trial of teverelix. This represents an optimum route for Antev and its investors to see the rapid development of its technology towards commercialization. I and Antev's talented team look forward to taking the company on to its next exciting stage." Before joining Antev, Mr Kohli was Chief Operating Officer at Pharnext SA ("Pharnext"), a Euronext listed advanced clinical-stage biopharmaceutical company, developing novel therapeutics for orphan neurodegenerative disorders. At Pharnext, Mr Kohli was responsible for leading corporate strategy and operations. Prior to Pharnext, Mr Kohli held leadership roles at Eurofins, Becton Dickinson and at Sanofi, encompassing sales, marketing, supply chain and manufacturing. Mr. Kohli earned an M.B.A. from the Management Development Institute (MDI) Gurgaon, in India and a Bachelor of Engineering from the University of Pune in India. For more information, please contact: Amit Kohli Antev Limited Tel: +44 (0) 20 7495 3053 Email: akohli@antev.co.uk Tarquin Edwards Peckwater PR Mob: +44 (0) 7879 458 364 Email: tarquin.edwards@peckwaterpr.co.uk About Teverelix and GnRH Antagonists Teverelix is an injectable, long-acting GnRH antagonist in a novel and unique microcrystal formulation, which is able to overcome the historic problems associated with other GnRH antagonist candidates in the treatment of prostate cancer. With good injection site tolerance and a potential six-week dosing interval, Antev management believe the therapeutic is likely to enjoy better compliance and therefore better outcomes. Teverelix also has the potential of being developed to address Benign Prostatic Hyperplasia (BPH), Acute Urinary Retention (AUR) and in women's health, endometriosis and Uterine Fibroids. About Antev Limited Antev is a late clinical-stage drug development company, based in London focused on the development of a robust registration-ready data package for the treatment of advanced prostate cancer. Antev was founded in 2013 and in 2014, the Company acquired the intellectual property rights for teverelix from LifeArc, one of the UK's leading medical research charities. LifeArc ( ) has extensive experience commercialising academic research having helped launch 12 drugs including Avastin®, Campath® and Herceptin® and having formed 18 start-ups including the UK's largest and most successful biotech companies, Celltech and CAT.[1] About Prostate Cancer Prostate cancer affects an estimated 1.3 million patients globally and is the second most common cause of cancer death in men.[2]. In spite of novel treatments being developed, androgen deprivation therapy (ADT) remains the foundation of care. [1] [2] Bray et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), pp.394-424. SOURCE: Antev Ltd View source version on accesswire.com:

100 Deals associated with Gonadorelin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Gonadorelin Hydrochloride	H01CA01 V04CM01	DB00644

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Infertility	United States	Hikma Pharmaceuticals USA, Inc.	30 Sep 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04037254 (CTgov)	Phase 1/2	Prostate Cancer, Hereditary, 7 \| Adenocarcinoma of prostate	22	Intensity-Modulated Radiation Therapy+Gonadotrophin Releasing Hormone+niraparib (Phase I, Dose Level 1 (Niraparib, GnRH, IMRT))	hemcbnbasm(qjredfibcu) = qvfcschxey caermpfiji (mhcqzmktcu, ojtvzeislo - fhotgbicft) View more	-	11 Jul 2025
				Intensity-Modulated Radiation Therapy+Gonadotrophin Releasing Hormone+niraparib (Phase I, Dose Level 2 (Niraparib, GnRH, IMRT))	hemcbnbasm(qjredfibcu) = jeesqfjlni caermpfiji (mhcqzmktcu, utybchgodm - mebmfnvjql) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis